F8 and hemophilia A: In the same year, another GT trial on 134 patients with severe hemophilia A who took one dose of Valoctocogene Roxaparvovec (An AAV5 encoding FVIII) revealed that the mean FVIII activity level for HIV-negative patients increased by 41.9 IU per deciliter.